Health And Wellness Industry Regulatory And Litigation News

FTC ends 9-party supplement claims enforcement with three last settlements; ginkgo class action against Nature’s Bounty dismissed; and litigation dismissed when suspect sexual enhancement supplements removed from website.

JST Distribution LLC alleged that eLine LP marketed drug-spiked competition to its “all-natural” sexual enhancement supplement, prompting eLine to remove the suspect products that a third-party was selling on its website, which led to JST agreeing to dismiss its litigation on Aug. 17. JST’s complaint filed April 28 in federal court in Los Angeles alleged violations of federal and state advertising laws and that brands FDA identified as products marketed as supplements but spiked with erectile dysfunction drug sildenafil were available through eLine on a website branded “Romantix.” The Spring, Texas, firm argued “eLine’s representations regarding these products are false and misleading,” notably the “Enhancement Products” labeled as supplements despite “unlawfully containing hidden drug ingredients.” However, eLine responded that it did not control Romantix’ inventory and while it “admits that some of the products identified in” JST’s complaint were offered on the Romantix website, no sales were recorded since before April 9 and the products were removed April 14. Also, the San Francisco online and conventional retailer said it “reasonably relies upon product manufacturers to provide information on their products,” and it “denies that it knowingly offered for sale any mislabeled product or any product containing sildenafil or any other chemical in sufficient amount to require a prescription for sale.”

JST, which noted in its complaint that FDA has reported “a growing trend in the supplement industry of mislabeling ‘dietary...

HBW Podcast

Explore how consumer health is evolving. On the go.

David Ridley hosts in-depth conversations with industry leaders.

More from Legal

Nancy Tests SPARC-1050 Again

 

This is a short description. This is a short description. This is a short description.

Deference No More: More Challenges Against US FDA After Supreme Court Tosses Chevron Doctrine?

 
• By 

The Supreme Court’s 6-3 ruling is expected to have a minimal impact on drug approvals and other scientific determinations, but matters steeped in the interpretation of regulation and statute, such as marketing exclusivity, could face a heightened risk of challenge, legal experts say.

Ordinary Marketing Or Consumer Trap? Talking ‘Dark Patterns’ With Attorney Lauren Aronson

 
• By 

Whether called “dark patterns,” “shady” online marketing practices, or simply deception on the internet, the issue has taken on high importance at the US Federal Trade Commission and is being tackled by new laws in a growing number of states. Amin Talati Wasserman partner Lauren Aronson discusses in this interview with HBW Insight.

FTC Might Need More Illumination On Proposed Rule For Online Consumer Product Reviews

 

BBB National Programs found FTC’s proposed Trade Regulation Rule on the Use of Consumer Reviews and Testimonials largely effective with some certainty on whether product reviews or customer testimonials are violations of its false advertising standards. But it =expects some clarifications may come in final rule.

More from Policy & Regulation

Kratom Industry Argues FDA Wants To Label All Products As Adverse Events Without Evidence

 

Week after publishing safety alert about OPMS Black Liquid Kratom “linked to serious adverse health effects, including death,” FDA announced market research “to understand and characterize emergent risk/safety and perceived benefits reportedly linked to kratom and psychedelics.” But it withdrew the study 10 days later.

ACNU Switch And IND Exemption Final Rules Targeted For October In FDA Regulatory Goals

 

Semi-annual regulatory agenda of non-binding target dates also sets December goal for an NPRM to recognize N-acetyl-L-cysteine as a lawful dietary ingredient. Like IND exemptions rule, item on NAC included for first time in FDA’s list.

'Inside Regulatory Affairs' With The Honest Company’s Sharee Crumbey And Monica Sharda

 
• By 

In this installment of HBW Insight’s “Inside Regulatory Affairs” series, we hear from Sharee Crumbey and Monica Sharda, regulatory affairs specialists at The Honest Company, about the mounting challenges and rewards of the job.